N-Acetyl Selank
An acetylated form of Selank with enhanced CNS penetration and bioavailability - producing anxiolytic, nootropic, and immune-modulatory effects via GABA and BDNF pathways.
⚠ Research & Educational Use Only. N-Acetyl Selank is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Enhanced bioavailability compared to native Selank - the N-acetyl modification improves stability and CNS penetration
- Anxiolytic effects without sedation or addiction potential - superior to benzodiazepines in this regard
- Enhances cognitive performance: working memory, learning speed, focus, and information processing
- N-Acetyl Selank is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Enhanced bioavailability compared to native Selank - the N-acetyl modification improves stability and CNS penetration
- Anxiolytic effects without sedation or addiction potential - superior to benzodiazepines in this regard
- Enhances cognitive performance: working memory, learning speed, focus, and information processing
- BDNF upregulation - promotes neuroplasticity and neuroprotection
What is N-Acetyl Selank?
N-Acetyl Selank is an acetylated analogue of Selank - itself a synthetic heptapeptide derived from the endogenous immunomodulatory peptide Tuftsin (Thr-Lys-Pro-Arg) with a Gly-Glu-Pro extension added to improve stability. The N-acetyl modification at the peptide's amino terminus further enhances stability against aminopeptidase enzymes and improves lipophilicity, which may enhance blood-brain barrier penetration and CNS bioavailability.
Selank was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences as an anxiolytic research compound with a superior safety profile compared to classical benzodiazepines. The challenge with benzodiazepines - GABA-A receptor positive allosteric modulators - is their potential for tolerance, dependence, and cognitive impairment. Selank's anxiolytic mechanism is multifactorial and includes GABA pathway modulation without direct benzodiazepine receptor binding, potentially achieving anxiolysis with less risk of dependence.
The mechanism of Selank and N-Acetyl Selank involves multiple targets: modulation of GABAergic transmission (the primary inhibitory neurotransmitter system), upregulation of BDNF (Brain-Derived Neurotrophic Factor, which promotes neuroplasticity and neuroprotection), regulation of serotonin metabolism, and effects on the enkephalinase enzyme system (which degrades endogenous opioid peptides). This multi-target profile may explain why Selank produces both anxiolytic and cognitive-enhancing effects simultaneously - many anxiolytics impair cognition by broadly suppressing CNS activity, but Selank appears to reduce anxiety while maintaining or improving cognitive performance.
The immunomodulatory properties of Selank are inherited from its Tuftsin-derived core. Tuftsin is a naturally occurring tetrapeptide produced from immunoglobulin G (IgG) that activates macrophages and natural killer cells. The inclusion of the Tuftsin-related sequence gives Selank a dual neurological-immune profile that has been studied in the context of stress-induced immunosuppression.
N-Acetyl Selank is often compared to and complementary with N-Acetyl Semax. The two are commonly combined in research protocols targeting anxiety, cognitive performance, and neuroprotection - with Semax providing more stimulating, BDNF-driven nootropic effects and Selank providing the calming, anxiety-reducing component.
Key Research Benefits
Documented effects observed in preclinical and clinical studies on N-Acetyl Selank. See all Cognitive Enhancement peptides for comparison.
Common Stacks
N-Acetyl Selank is frequently combined with the following peptides for synergistic effects. Click any peptide to compare profiles before deciding.
BPC-157's tissue healing and gut-protective effects complement Thymosin Alpha-1's immune activation for comprehensive recovery and immune support.
Both are anti-inflammatory peptides with complementary mechanisms: Thymosin Alpha-1 via T cell activation, VIP via cytokine suppression.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports.
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
N-Acetyl Selank is typically dosed at 250-750 mcg per day, via subcutaneous injection or intranasal spray.
Standard research dose: 250-500 mcg per day Intranasal dose: 2-3 drops per nostril, 2-3 times daily (at 0.15% solution) Cycle: 2-4 weeks on, 1-2 weeks off to maintain sensitivity Often compared to and combined with N-Acetyl Semax for complementary anxiolytic + cognitive enhancement
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
For injection: reconstitute with bacteriostatic water, administer subcutaneously once daily. For intranasal: use a 0.15% solution nasal spray, 2-3 sprays per nostril, 2-3 times per day. Intranasal administration offers convenient, injection-free dosing with good bioavailability.
Explore Further
Quick Reference
Research Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.